Dyskinesia Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyskinesia pipeline constitutes 40+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dyskinesia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market.

The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dyskinesia Pipeline Report: https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years.
• Dyskinesia companies working in the treatment market are Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment
• Emerging Dyskinesia therapies in the different phases of clinical trials are- CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In March 2022, The use of DYSVAL capsules 40mg, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, as treatments for tardive dyskinesia has received regulatory approval from the Ministry of Health, Labour, and Welfare.
• In December 2021, A co-promotion agreement has been reached between Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. for the co-marketing of MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor that is marketed in Japan as a treatment for tardive dyskinesia.
• In November 2021, South Korea granted Valbenazine (INGREZZA) by Mitsubishi Tanabe Pharma Corporation approval as a tardive dyskinesia treatment.
• In September 2021, The National Medical Products Administration (NMPA) of China's Centre for Drug Evaluation (CDE) has approved the next-generation Vesicular Monoamine Transporter 2 (VMAT2) inhibitor drug LY03015 for clinical trials as a Class 1 new drug for the indication in TD, according to a Luye Pharma Group announcement.
• According to Neurocrine Biosciences, Inc.'s 2021 annual report, the business set aside USD 328.1 million for product research and development. However, only a part of that amount, precisely USD 50.5 million, was used for the actual research and discovery process.

Dyskinesia Overview
A movement disorder called dyskinesia frequently manifests as uncontrollable tremors, tics, or shakes. Because drugs that boost dopamine in the brain overstimulate dopamine receptors, the disorder frequently affects persons with Parkinson's disease.

Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• CP 011: Contera Pharma
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010 : Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma

Dyskinesia Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Dyskinesia Molecule Type
Dyskinesia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Dyskinesia Pipeline Therapeutics Assessment
• Dyskinesia Assessment by Product Type
• Dyskinesia By Stage and Product Type
• Dyskinesia Assessment by Route of Administration
• Dyskinesia By Stage and Route of Administration
• Dyskinesia Assessment by Molecule Type
• Dyskinesia by Stage and Molecule Type

DelveInsight's Dyskinesia Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dyskinesia Therapeutics Market include:
Key companies developing therapies for Dyskinesia are - SOM BIOTECH, Luye Pharma Group, Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation), Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., and others.

Dyskinesia Pipeline Analysis:
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dyskinesia drugs and therapies-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyskinesia Pipeline Market Drivers
• Increase in prevalence of Dyskinesia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Dyskinesia Market.

Dyskinesia Pipeline Market Barriers
• However, lack of understanding of the pharmacology of Dyskinesia, side-effects associated with drugs and other factors are creating obstacles in the Dyskinesia Market growth.

Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Dyskinesia Companies: Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
• Key Dyskinesia Therapies: CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers

Request for Sample PDF Report for Dyskinesia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dyskinesia Report Introduction
2. Dyskinesia Executive Summary
3. Dyskinesia Overview
4. Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5. Dyskinesia Pipeline Therapeutics
6. Dyskinesia Late Stage Products (Phase II/III)
7. Dyskinesia Mid Stage Products (Phase II)
8. Dyskinesia Early Stage Products (Phase I)
9. Dyskinesia Preclinical Stage Products
10. Dyskinesia Therapeutics Assessment
11. Dyskinesia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dyskinesia Key Companies
14. Dyskinesia Key Products
15. Dyskinesia Unmet Needs
16 . Dyskinesia Market Drivers and Barriers
17. Dyskinesia Future Perspectives and Conclusion
18. Dyskinesia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Dyskinesia Market https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Dyskinesia Epidemiology https://www.delveinsight.com/report-store/dyskinesia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.